U.S. Renal Biomarkers Market (2025 - 2033) Size, Share & Trend Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays, Clinical Chemistry Assays), By End-use (Hospitals & Clinics, Diagnostic Laboratories), And Segment Forecasts

Market Segmentation

U.S. Renal Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
- Functional Biomarkers
  - Serum Creatinine
  - Blood Urea Nitrogen (BUN)
  - Estimated Glomerular Filtration Rate (eGFR)
- Upregulated Proteins
  - Kidney Injury Molecule-1 (KIM-1)
  - Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  - Cystatin C
  - Interleukin-18 (IL-18)
  - Others
- Other Novel Biomarkers
  - microRNA biomarkers
  - Proteomic/metabolomic markers
U.S. Renal Biomarkers Diagnostic Technique Outlook (Revenue, USD Million, 2021 - 2033)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunoassays
- Clinical Chemistry Assays
- Point-of-Care Testing (POCT) Devices
- Molecular Diagnostics
- Other Emerging Platforms
U.S. Renal Biomarkers End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments